Company / Interest Expense
NEKTAR THERAPEUTICS Interest Expense History
FY2016-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
-
FY2022
5-year range
$0 / $0
FY2018-FY2022
Trend
-
vs FY2021
Sector context
#40 of 44
Health Care
What the data says
Improved from $22M to $0 over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 9% in Health CareTop 9% of 44
▼
Key checks
Key Insights
- Peak interest expense was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score -11.97 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $0 | - |
| FY2021 | $0 | -100.0% |
| FY2020 | $21.6M | -2.3% |
| FY2019 | $22.1M | -1.7% |
| FY2018 | $22.5M | +1.7% |
| FY2017 | $22.1M | +23.6% |
| FY2016 | $17.9M | -2.3% |
As of FY2022 · SEC 10-K · Updated Jun 30, 2026